US · biotechnology · oncology · pharmaceutical
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series D · Aug 2026 · $67M
SymBiosis lead, SR One lead, Medicxi lead, Wellington Management, Samsung, LG Technology Ventures, OrbiMed Advisors, Novartis Venture Fund, HBM Healthcare Investments, Primer Ventures, 3B Capital, Axil, Cormorant Capital, TaiAx, Windham Life Science Partners
Reported by Ventureburn
Missing a round, or an investor who was in one? Tell us.